NASDAQ · TRAW
Traws Pharma, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TRAW: Nov 12, 2026
Traws Pharma, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.21. The reported EPS for the same quarter last year was $-0.34.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Dec 2026 | $-0.19 | $-0.19 | $-0.19 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Fintel · Quiver Quantitative- RTTNews · May 8, 9:20 AM EDTTraws Climbs 20% On Hantavirus Drug Development Push(RTTNews) – Traws Pharma Inc. (TRAW), a clinical-stage biopharmaceutical company, on Friday announced plans to advance potential clinical candidates for the treatment and prevention of Hantavirus infections.
- Zacks · Apr 20, 9:55 AM EDTTraws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Traws Pharma, Inc. (TRAW) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a
- RTTNews · Apr 15, 9:01 AM EDTTraws Pharma Secures Up To $60 Mln Financing To Advance Influenza Program(RTTNews) – Traws Pharma Inc. (TRAW) announced a private investment in public equity ("PIPE") financing that could bring up to $60 million, aimed at supporting its influenza program through planned human challenge trial in the United Kingdom.
- RTTNews · Feb 19, 9:25 AM ESTTraws Pharma Stock Plunges As FDA Halts TXM IND(RTTNews) – Shares of Traws Pharma Inc (TRAW) are down over 28%, on news of its US IND for Tivoxavir marboxil being placed on clinical hold by the FDA due to concerns with the mutagenicity data package.
- RTTNews · Jan 27, 1:56 AM ESTTraws Pharma Completes Enrollment In Phase 2 Study Of Ratutrelvir; Expands TXM To Influenza(RTTNews) – Traws Pharma Inc. (TRAW) has announced the completion of enrollment in its ongoing Phase 2 study comparing Ratutrelvir with PAXLOVID in patients with mild to moderate COVID-19, as well as in a single arm in PAXLOVID-ineligible subjects.
- RTTNews · Jan 14, 10:41 PM ESTPlus Therapeutics Spurs After-Hours Biotech Rally; Connect Biopharma And Elutia Also Advance(RTTNews) – Biotech and healthcare names were among the notable movers in Wednesday's after-hours trading session, with several small-cap companies posting strong gains on the back of corporate updates and investor momentum.
- RTTNews · Jan 13, 8:03 AM ESTTraws Pharma Announces IND Filing Of Tivoxavir Marboxil(RTTNews) – Traws Pharma, Inc. (TRAW) announced the filing of a U.S. IND application with the FDA for tivoxavir marboxil, a potential CAP-dependent endonuclease inhibitor as a single oral tablet administered for the treatment of influenza.
- RTTNews · Dec 17, 7:37 AM ESTTraws' Ratutrelvir Shows Activity In PAXLOVID-Ineligible COVID-19 Patients; Final Data Due In Jan.(RTTNews) – Traws Pharma, Inc. (TRAW) reported positive interim data from its ongoing Phase 2 study of Ratutrelvir in patients with mild-to-moderate COVID-19 who are ineligible for Paxlovid, Pfizer's oral antiviral.
- RTTNews · Dec 14, 9:51 PM ESTMarket Pulse: Tilray Leads After-Hours Rally As Biotech Peers Surge(RTTNews) – A quiet news day didn't stop several high-volatility healthcare and cannabis stocks from posting sharp after-hours gains on Friday, with traders leaning into recent catalysts and technical momentum.
- Fintel · Dec 3, 7:06 PM ESTHC Wainwright & Co. Initiates Coverage of Traws Pharma (TRAW) with Buy RecommendationFintel reports that on December 3, 2025, HC Wainwright & Co. initiated coverage of Traws Pharma (NasdaqCM:TRAW) with a Buy recommendation. Analyst Price Forecast Suggests 6,983.33% Upside
- Quiver Quantitative · Jun 30, 6:40 AM EDTTraws Pharma Submits Phase 2 Protocols for Tivoxavir Marboxil and Ratutrelvir to HREC and FDATraws Pharma submitted Phase 2 protocols for TXM and ratutrelvir to evaluate treatments for flu and COVID-19.
- Quiver Quantitative · Jun 3, 7:12 AM EDTTraws Pharma Publishes Clinical Efficacy Data for Rigosertib in RDEB-Associated Squamous Cell CarcinomaTraws Pharma published promising data on rigosertib for treating RDEB-associated SCC, showing an 80% response rate in clinical trials.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Traws Pharma, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.